ArticleJCO clinical cancer informatics2018
Technology Applications: Use of Digital Health Technology to Enable Drug Development.
Article in JCO clinical cancer informatics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.Gynecologic oncology · 2024Trial
- International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Cancer Clinical Trial Patients' Perceptions of Reporting Adverse Events Via an Electronic Platform.Therapeutic innovation & regulatory science · 2025Article
- Drug response in the era of precision medicine: A methodological review.Computational and structural biotechnology journal · 2025Review
- Article
- Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.Journal of immunotherapy and precision oncology · 2024Review
- New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology.NPJ precision oncology · 2024Review
- The Extent of Engagement With Telehealth Approaches by Patients With Advanced Cancer: Systematic Review.JMIR cancer · 2022Review
- Strategies for improving the management of immune-related adverse events.Journal for immunotherapy of cancer · 2020Article
- Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Review
- Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer.Cancer · 2020Article
- Innovations in research and clinical care using patient-generated health data.CA: a cancer journal for clinicians · 2020Review
- Intersection of Digital Health and Oncology.JCO clinical cancer informatics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib. PATIENTS AND
methodseCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring. eCO links to a Bluetooth-enabled blood pressure (BP) monitor and transmits data to a secure provider web portal. eCO use was assessed for suitability, usability, and satisfaction after 4 weeks using a 17-item questionnaire. Metrics regarding patient-reported BP and diarrhea events were analyzed.
resultsSixteen patients enrolled in the pilot. A total of 98.2% of expected BP values were reported: 94.2% via Bluetooth and 5.8% entered manually. Twelve patients experienced 21 BP events (systolic BP > 140 and/or diastolic BP > 90 mmHg on two consecutive readings); data from cycle 1 were comparable to the study database. Thirteen patients reported diarrhea (more than one stool per 24 hours over baseline) categorized as grade 1 or 2, which was comparable to the study database. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their health care team. The only aspect of the application that did not show a statistically significant positive response was the process of reporting diarrhea.
conclusionThe eCO application was designed to assist in managing acute treatment-related events most often associated with treatment discontinuation, need for drug holidays, or dose interruption. Hypertension and diarrhea events reported via eCO allowed rapid provider response and a positive overall patient experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.